Order Article Reprints

Kuo C-Y, Tsai M-J, Hung J-Y, Wu K-L, Tsai Y-M, Tsai Y-C, Chuang C-H, Lee T-H, Chen H-C, Yang C-J, et al. Different Tyrosine Kinase Inhibitors Used in Treating EGFR-Mutant Pulmonary Adenocarcinoma with Brain Metastasis and Intracranial Intervention Have No Impact on Clinical Outcomes. Cancers. 2023; 15(1):187. https://doi.org/10.3390/cancers15010187

Kuo, Chia-Yu, Ming-Ju Tsai, Jen-Yu Hung, Kuan-Li Wu, Ying-Ming Tsai, Yu-Chen Tsai, Cheng-Hao Chuang, Tai-Huang Lee, Huang-Chi Chen, Chih-Jen Yang, and et al. 2023. "Different Tyrosine Kinase Inhibitors Used in Treating EGFR-Mutant Pulmonary Adenocarcinoma with Brain Metastasis and Intracranial Intervention Have No Impact on Clinical Outcomes" Cancers 15, no. 1: 187. https://doi.org/10.3390/cancers15010187

Kuo, C.-Y., Tsai, M.-J., Hung, J.-Y., Wu, K.-L., Tsai, Y.-M., Tsai, Y.-C., Chuang, C.-H., Lee, T.-H., Chen, H.-C., Yang, C.-J., & Chong, I.-W. (2023). Different Tyrosine Kinase Inhibitors Used in Treating EGFR-Mutant Pulmonary Adenocarcinoma with Brain Metastasis and Intracranial Intervention Have No Impact on Clinical Outcomes. Cancers, 15(1), 187. https://doi.org/10.3390/cancers15010187